By: Courtney Marabella From: onclive.com Data from the pivotal phase 3 KATHERINE (NCT01772472) has led to the addition of ado-trastuzumab emtansine (T-DM1; Kadcyla) to the HER2-positive breast cancer treatment arsenal, but the toxicities associated with the approach must be appropriately managed so that patients can continue to receive it, according to Jane L. Meisel, MD. The phase 3 KATHERINE trial …
Antibody-Drug Conjugates, TKIs Drive Improved Outcomes in HER2+ Breast Cancer
By: Caroline Seymour From: onclive.com The practice-changing treatment regimens that were evaluated in the pivotal KATHERINE, HER2CLIMB, and DESTINY-Breast01 trials in women with HER2-positive breast cancer are pushing the needle forward in making this breast cancer subtype a chronic disease. The practice-changing treatment regimens that were evaluated in the pivotal KATHERINE, HER2CLIMB, and DESTINY-Breast01 trials in women with HER2-positive breast …
Pivotal Trials Lead to Transformative Approaches in HER2+ Breast Cancer
By: Caroline Seymour From: onclive.com Four pivotal trials––KATHERINE, FeDeriCa, DESTINY-Breast01, and HER2CLIMB have not only amplified the armamentarium in HER2-positive breast cancer, but have illustrated the importance of neoadjuvant therapy, alternative administration methods, high-potency HER2-targeted therapy, and inclusion of all-comers with brain metastases in clinical trials. In a presentation during the 2020 Institutional Perspectives in Cancer webinar on breast cancer, …
NICE Approves Adjuvant Trastuzumab for HER2-positive Early Breast Cance
By: Dawn O’Shea From: medscape.com The National Institute for Health and Care Excellence (NICE) has approved trastuzumab emtansine as an option for the adjuvant treatment of human epidermal growth factor receptor 2 (HER2)‑positive early breast cancer in adults who have residual invasive disease in the breast or lymph nodes after neoadjuvant taxane-based and HER2‑targeted therapy. Trastuzumab is an adjuvant …